Multi OIT to Test Immune Markers After Minimum Maintenance Dose

NCT03181009 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Food Allergy

Interventions

DRUG: Omalizumab
DRUG: Food Flour Allergens

Sponsor

Andrew Long, PharmD

Collaborators

[object Object]